ライフサイエンスコーパス: A(1) receptor

1 ed by PD81723, an allosteric enhancer of the A1 receptor.

2 y DPCPX, indicating a prominent role for the A1 receptor.

3 ow are mediated by adenosine but not via the A1 receptor.

4 uld be ameliorated by blocking the adenosine A1 receptor.

5 y formed adenosine can chaperone its cognate A1 receptor.

6 ffinity indistinguishable from the wild-type A1 receptor.

7 indings were recapitulated for the wild-type A1 receptor.

8 ive consequences through a pathway involving A1 receptors.

9 tonically inhibited by adenosine acting via A1 receptors.

10 siently be provoked after blocking adenosine A1 receptors.

11 , metabotropic glutamate mGlu5 and adenosine A1 receptors.

12 ells showed enhanced responses to M2 but not A1 receptors.

13 rescued presynaptic inhibition by adenosine A1 receptors.

14 vealed greater A2B selectivity over A2A than A1 receptors.

15 amidal neurons via activation of presynaptic A1 receptors.

16 ogeneous activation of presynaptic adenosine A1 receptors.

17 ulsant acting on excitatory synapses through A1 receptors.

18 opentyl-1,3-dipropylxanthine (100 nM) at the A(1) receptor.

19 denosine A(2a) receptor versus the adenosine A(1) receptor.

20 is 16 500-fold selective with respect to the A(1) receptor.

21 d an affinity of 7 nM on the human adenosine A(1) receptor.

22 g that the response was mediated entirely by A(1) receptors.

23 ity by adenosine is mediated via presynaptic A(1) receptors.

24 m channels, but involves adenosine acting at A(1) receptors.

25 duced by adenosine in hypoxia is mediated by A(1) receptors.

26 e is mediated by the activation of adenosine A(1) receptors.

27 ansmission through activation of presynaptic A(1) receptors.

28 -X-BY630 dissociation were much lower at the A(1) receptor (1.5-, 1.4-, and 1.5-fold).

29 ateral RA had significantly higher adenosine A1 receptor (2.7+/-1.7-fold; P<0.01) and GIRK4 (1.7+/-0.

30 , Ki=7 nM) and selectivity for the adenosine A1 receptor (915-fold versus adenosine A2A receptor; 12-

31 Adenosine A(1) receptor (A(1)AR) agonists have antinociceptive eff

32 hrough sustained activation of the adenosine A(1) receptor (A(1)R) and phospholipase C-mediated deple

33 Activation of adenosine A(1) receptor (A(1)R) by N(6)-cyclopentidyladenosine (CP

34 ulators of agonist function at the adenosine A(1) receptor (A(1)R) in two different functional assays

35 onate, ACP) directly activated the adenosine A(1) receptor (A(1)R).

36 e(-/-) mice and were eliminated in Adenosine A(1) receptor (A(1)R, Adora1) knock-out mice.

37 Adenosine A(1) receptors (A(1)AR) are well characterized for their

38 y and heart failure, but the contribution of A(1) receptors (A(1)R) and A(3) receptors (A(3)R) is not

39 d by activation of either H(3)R or adenosine A(1) receptors (A(1)R).

40 ecently, a mutation in the gene encoding the A(1)-receptor (A(1)R), A(1)R-G279S(7.44), was identified

41 s more pronounced in a mutant version of the A(1)-receptor (A(1)R-G279S(7.44)), which was identified

42 esis that a partial agonist of the adenosine A1 receptor (A1AdoR) may cause a greater attenuation of

43 is study, we targeted the cochlear adenosine A1 receptor (A1AR) by trans-tympanic injections of the a

44 In this study, we show that the adenosine A1 receptor (A1AR) protects against cisplatin ototoxicit

45 Adenosine A1 receptor (A1AR) subtype present on renal proximal tub

46 Allosteric modulation of adenosine A1 receptors (A1ARs) offers a novel therapeutic approach

47 Neurabin attenuated adenosine A(1) receptor (A1R) signaling by assembling a complex be

48 -term depression (LTD) mediated by adenosine A1 receptor (A1R) activation at corticostriatal synapses

49 of A1 receptor signaling using an adenosine A1 receptor (A1R) antagonist, 8-cyclopentyl-1,3-dimethyl

50 cortical actin polymerization via adenosine A1 receptor (A1R) induction of a Rho GTPase CDC42-depend

51 The adenosine A1 receptor (A1R) is a key mediator of the neuroprotecti

52 activity through activation of the adenosine A1 receptor (A1R), resulting in antinociception and high

53 synapses resulting in an enhanced adenosine A1 receptor (A1R)-dependent protective tone despite lowe

54 ate adenosine concentration and/or adenosine A1 receptors (A1R) in the brain.

55 This action is shared by adenosine A(1) receptors (A1Rs), which are also located on Sc term

56 s a neuromodulator acting through inhibitory A1 receptors (A1Rs) and facilitatory A2ARs, which have s

57 The suppression was mediated by presynaptic A1 receptors (A1Rs) because it was blocked by a selectiv

58 Activation of presynaptic adenosine A1 receptors (A1Rs) causes substantial synaptic depressi

59 Adenosine A1 receptors (A1Rs) in human and rodent brains can be vi

60 hippocampal neurons, activation of adenosine A1 receptors (A1Rs) or GABA(B) receptors on synaptic ter

61 n mice by increasing activation of adenosine A1 receptors (A1Rs).

62 rosynaptic plasticity; blockade of adenosine A1 receptors abolished it.

63 rosynaptic plasticity: blockade of adenosine A1 receptors abolished weight dependence, while increase

64 n of internal Ca(2+) stores, suggesting that A(1) receptor activation leads to an increase in IP(3),

65 the latter being mediated, in part, through A(1) receptor activation on airway smooth muscle.

66 crotic death, and this can be ameliorated by A(1) receptor activation or A(2A) receptor blockade.

67 n synaptic activity was reduced by adenosine A(1) receptor activation, and a combination of Ca(2+) an

68 stimulation of astrocytes and the consequent A(1) receptor activation.

69 Adenosine A1 receptor activation also impaired the expression of b

70 fect of acupuncture is mediated by adenosine A1 receptor activation at the acupuncture point, we here

71 Adenosine A1 receptor activation depresses excitatory transmission

72 However, endogenous A1 receptor activation during cortical seizures in vivo

73 Given the central role demonstrated for A1 receptor activation in determining synaptic amplitude

74 d excitatory neurotransmission via adenosine A1 receptor activation in spinal cord slices from wild-t

75 of trigeminovascular nociception, adenosine A1 receptor activation leads to neuronal inhibition with

76 nal efficacy and therefore the heterogeneous A1 receptor activation seen in the mature neocortex appe

77 echanical allodynia via peripheral adenosine A1 receptor activation.

78 Adenosine elicits cardioprotection through A1-receptor activation.

79 we report a novel dual role of the adenosine A1 receptor (Adora1) as an E2/ERalpha target and a regul

80 potential glucagon inhibitor, the adenosine A1 receptor (Adora1), is gradually diminished in alpha-c

81 e thought to require activation of adenosine A1 receptors (adorA1Rs) and release of transmitter molec

82 he G279S substitution on the activity of the A(1)-receptor after heterologous expression in HEK293 ce

83 After diclofenac, the A(1) receptor agonist CCPA evoked no vasodilatation: we

84 d adult rat ventricular myocytes (ARVM), the A(1) receptor agonist cyclopentyladenosine (CPA) inhibit

85 Treatment with an A(1) receptor agonist decreases EPSC amplitude and reduc

86 The adenosine A(1) receptor agonist N(6)-cyclohexyladenosine (CHA) ind

87 hwork cells to the addition of the adenosine A(1) receptor agonist N(6)-cyclohexyladenosine (CHA).

88 ine, N(6)-cyclopentyladenosine (an adenosine A(1) receptor agonist), and 2-[p-(2-carboxyethyl)]phenyl

89 ylxanthine (CPDX; 5 microM and 50 microM) or A(1) receptor agonist, N(6)-cyclopentyladenosine (CPA; 5

90 tion were reduced in mutants treated with an A(1) receptor agonist, whereas an A(2A) receptor agonist

91 The A1 receptor agonist 2-Chloro-N6-cyclopentyladenosine (CC

92 The selective A1 receptor agonist 2-chloro-N6-cyclopentyladenosine (CC

93 te receptor antagonist MK-801; the adenosine A1 receptor agonist 2-chloro-N6-cyclopentyladenosine (CC

94 These data are consistent with adenosine A1 receptor agonist actions on REM sleep mediated throug

95 rats were treated IT with the selective Ado A1 receptor agonist cyclohexyladenosine (CHA) or vehicle

96 cholinergic neurons, the selective adenosine A1 receptor agonist N6-cyclohexyladenosine, administered

97 Microinjection of adenosine A1 receptor agonist or an inhibitor of adenylyl cyclase

98 Direct injection of an adenosine A1 receptor agonist replicated the analgesic effect of a

99 cked by exogenous adenosine or the selective A1 receptor agonist, 2-chloro-N6-cyclopentyl adenosine.

100 lices containing the PnOc incubated with the A1 receptor agonist, cyclohexaladenosine (10(-8) M).

101 The selective low efficacy adenosine A1 receptor agonist, GR190178 (30-1000 microg/kg i.v.),

102 nistration of the highly selective adenosine A1 receptor agonist, GR79236 (3-100 microg/kg) had a dos

103 ialanate, a first-in-class partial adenosine A1 receptor agonist, has the potential to improve severa

104 ystemic injection of the selective adenosine A1 receptor agonist, N(6)-cyclohexyladenosine (CHA; 0.3

105 5.5% with SfA; P<0.001), CCPA (the adenosine A1-receptor agonist, 200 nmol/L) (24.9+/-4.5% versus 54.

106 ts of capadenoson (CAP), a partial adenosine A1-receptor agonist, on left ventricular (LV) function a

107 A(1) receptor agonists, but not other purinoceptor-type

108 Intrathalamic infusion of A1 receptor agonists directly reduces tremor, whereas ad

109 derable literature to suggest that adenosine A1 receptor agonists may have anti-nociceptive effects,

110 tric oxide synthase inhibitors and adenosine A1 receptor agonists.

111 lts support development of partial adenosine A1-receptor agonists for the treatment of chronic heart

112 Therapy with adenosine A1-receptor agonists, however, is limited by undesirable

113 distributions that spanned those of both the A1 receptor agonized and antagonized conditions.

114 Blockade of A1 receptors ameliorated the depression caused by adenos

115 Allosteric enhancers of the adenosine A1 receptor amplify signaling by orthosteric agonists.

116 To confirm the involvement of adenosine A(1) receptors and matrix metalloproteinases (MMP) in an

117 about 2 and 8 K when compared with wild-type A(1)-receptor and A(1)R-Y288A(7.53) (a folding-deficient

118 eceptor, dopamine transporter, and adenosine A1 receptor and decreased adenosine A2A receptor express

119 ion was blocked in the presence of adenosine A1 receptor and GABAB receptor blockade.

120 were combined with homology modeling of the A1 receptor and in silico screening of an allosteric enh

121 A areas with highest expression of adenosine A1 receptor and its downstream GIRK (G protein-coupled i

122 (R)-phenylisopropyl]adenosine from rat brain A1 receptors and [3H]2-[p-(2-carboxyethyl)phenyl-ethylam

123 the similar involvement of NMDARs, adenosine A(1) receptors, and PP1 in depotentiation of LTP caused

124 which was prevented by blockade of adenosine A1 receptors, and decreased expression of genes involved

125 racellular Ado, activation of inhibitory Ado A1 receptors, and decreased seizure generation, the desi

126 at is mediated mainly by adenosine acting on A1 receptors, and that the vasoconstrictor effects of sy

127 itive potassium (K(ATP)) channels, adenosine A1 receptors, and the effects of different levels of hal

128 ilocapnic HVR; (2) these impairments require A1 receptors; and (3) SF of OSA may exacerbate OSA via i

129 tor than in those cells expressing the human A1 receptor (ANOVA and posttest comparison, P<0.01).

130 Moreover, adenosine A1 receptor antagonism had larger effects on theta respo

131 ac arrhythmias and seizures due to adenosine A1-receptor antagonism.

132 LTF (85 +/- 11%, P < 0.05), but an adenosine A(1) receptor antagonist (DPCPX, 3 microg kg(-1), 10 mic

133 t 8-sulphophenyltheopylline (8-SPT), nor the A(1) receptor antagonist 8-cyclopentyl-1,3-dipropylxanth

134 yl-adenosine (CPA, 10 nM) and blocked by the A(1) receptor antagonist 8-cyclopentyl-1,3-dipropylxanth

135 were not altered by the selective adenosine A(1) receptor antagonist 8-cyclopentyl-1,3-dipropylxanth

136 oxic response, is inhibited by the adenosine A(1) receptor antagonist 8-cyclopentyl-1,3-dipropylxanth

137 The adenosine A(1) receptor antagonist 8-cyclopentyltheophylline (CPT)

138 Furthermore, the A(1) receptor antagonist 8-cyclopentyltheophylline (CPT)

139 Pretreatment with the adenosine A(1) receptor antagonist CPT (10 microM) or the nonselec

140 o characterization of a dual adenosine A(2A)/A(1) receptor antagonist in several animal models of Par

141 Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM;

142 quantified after microinjecting an adenosine A(1) receptor antagonist into the prefrontal cortex.

143 inal fluid (aCSF) and two doses of adenosine A(1) receptor antagonist, 1,3-dipropyl-8-phenylxanthine

144 d in preparations treated with the adenosine A(1) receptor antagonist, 8-cyclopentyl-1,3-dimethylxant

145 ion in mutants much more effectively than an A(1) receptor antagonist.

146 The adenosine A1 receptor antagonist 1,3-dipopylcyclopentylxanthine pr

147 0.9%) by systemic injection of the adenosine A1 receptor antagonist 8-CPT (2.5 mg kg(-1)) approximate

148 Both the adenosine A1 receptor antagonist 8-cyclopentyl-1,3-dipropylxanthin

149 ibitor l-NAME (Group 1, n = 8) and adenosine A1 receptor antagonist 8-cyclopentyl-1,3-dipropylxanthin

150 The adenosine A1 receptor antagonist 8-cyclopentyl-1,3-dipropylxanthin

151 Since the sleep-suppressing effects of the A1 receptor antagonist CPT were prevented following inhi

152 or administration of the selective adenosine A1 receptor antagonist dipropylcyclopentylxanthine (DPCP

153 The adenosine A1 receptor antagonist DPCPX did not affect the resting

154 acerebroventricular infusion of an adenosine A1 receptor antagonist produced a similar decrease in se

155 Here, we show that the adenosine A1 receptor antagonist rolofylline (KW-3902) is alleviat

156 Randomized Study of the Selective Adenosine A1 Receptor Antagonist Rolofylline for Patients Hospital

157 ble to that of BG9928, a selective adenosine A1 receptor antagonist that is currently in clinical tri

158 ropylxanthine (DPCPX), a selective adenosine A1 receptor antagonist that is permeable to the blood br

159 Imidazoline 14 is a competitive adenosine A1 receptor antagonist with a pA2 value of 8.88 and is h

160 (4H)-one, is a particularly potent adenosine A1 receptor antagonist with good selectivity over the ot

161 In the search for a selective adenosine A1 receptor antagonist with greater aqueous solubility t

162 of SPWs in slices treated with an adenosine A1 receptor antagonist, a finding that links the present

163 ed with either a glial toxin or an adenosine A1 receptor antagonist.

164 protein kinase A inhibitor and an adenosine A1 receptor antagonist.

165 F and volume overload, KW-3902, an adenosine A1-receptor antagonist, enhances the response to loop di

166 is that the use of rolofylline, an adenosine A1-receptor antagonist, would improve dyspnea, reduce th

167 sine receptor agonists but adenosine A(2) or A(1) receptor antagonists 3,7-dimethyl-1-propargyl xanth

168 Adenosine A(1) receptor antagonists have been used effectively as

169 haracterization of two, dual adenosine A(2A)/A(1) receptor antagonists in several animal models of Pa

170 Compounds 13 and 14 are potent dual A(2A)/A(1) receptor antagonists that have excellent activity,

171 ion were abolished or prevented by adenosine A1 receptor antagonists (50 mumol/L theophylline/1 mumol

172 Pertinent to this, brief applications of A1 receptor antagonists immediately after theta stimulat

173 eizures, a known potential adverse effect of A1-receptor antagonists.

174 Activation of the adenosine A(1)-receptor antagonizes responses elicited by dopamine

175 After microdialysis perfusion of A1 receptor antisense in the basal forebrain, spontaneou

176 In airway epithelium, A(2B) and A(1) receptors are implicated in the control of Cl(-) an

177 direct pathway, dopamine D(1)- and adenosine A(1)-receptors are coexpressed and are mutually antagoni

178 lic imidazoline antagonists of the adenosine A1 receptor are described.

179 se effects are mediated by A1 receptors, but A1 receptors are expressed in most brain regions, and di

180 ncreased neuronal excitability via adenosine A(1) receptors, ATP receptors, and ecto-ATPase.

181 eatments, we studied the effect of adenosine A(1) receptor blockade or deletion on bone density.

182 ibition of nucleotide breakdown or adenosine A1 receptor blockade and reduced by apyrase inactivation

183 Thus, A1 receptor blockade enhances and A2a receptor blockade

184 d during P2X receptor blockade with NF279 or A1 receptor blockade with 1,3-dipropyl-8-cyclopentylxant

185 uate the dose-dependent effects of adenosine A1-receptor blockade on diuresis and renal function in p

186 ability that were almost coincident with the A1 receptor blocked condition; however, mature synapses

187 The A1 receptor blocker DPCPX did not alter autoregulatory b

188 RPV4 channel, GABAB, as well as an adenosine A1 receptor blocker.

189 IRK channel activation mediated by adenosine A(1) receptors, but not GABA(B) receptors.

190 Many of these effects are mediated by A1 receptors, but A1 receptors are expressed in most bra

191 thway can be inhibited through activation of A1 receptors by adenosine.

192 Activation of A1 receptors causes inhibition of adenylate cyclase, dec

193 maphorins signal through neuropilin-2/plexin-A1 receptor complexes on post-crossing commissural axons

194 ypothesis that changes in both adenosine and A1 receptor concentrations can capture changes in cognit

195 ctivity, we examined their action on several A1 receptor constructs, including (1) species variants,

196 Adenosine A1 receptor control of the homeostatic regulation of sle

197 the present work, we tested whether blocking A1 receptors could enhance the damage to DAergic and GAB

198 The K+ efflux resulting from A1-receptor-coupled KATP-channel activation facilitates

199 sults were not associated with variations in A1 receptor densities and may instead reflect regional a

200 middle-aged slices and thereby activates the A1 receptor-dependent LTP reversal effect.

201 Furthermore, M2 and A1 receptors differentially use Galphai2 and Galphao and

202 long-term exposure to caffeine did not alter A1 receptor expression at the acupuncture point.

203 e SAN structure, SAN function, and adenosine A1 receptor expression in control (n=17) and 4-month tac

204 affeine during adulthood increased adenosine A1 receptor expression in the NAc, but no other protein

205 anti-nociceptive actions required adenosine A1 receptor expression.

206 ucted to examine the importance of adenosine A1 receptors for the acquisition and expression of hippo

207 this response to adenosine, but deletion of A1 receptors from CA1 neurons had no effect, demonstrati

208 Deletion of A1 receptors from CA3 neurons abolished this response to

209 ht be attributable to the enhanced adenosine A1 receptor function on synaptic transmission, and the d

210 protein-coupled receptors (GPCRs) (adenosine A(1) receptors, GABA(B) receptors, metabotropic glutamat

211 ateral RA regions with the highest adenosine A1 receptor/GIRK4 expression.

212 To inhibit K(ATP) channels or adenosine A1 receptors, glibenclamide (0.1 mg/kg icv; n = 8), 5-hy

213 tor and good selectivity with respect to the A(1) receptor (>200-fold in some cases).

214 thiopyrimidines as selective human adenosine A1 receptor (hA1AR) agonists with tunable binding kineti

215 However, blockade of A1 receptors had no effect on BOLD responses and did not

216 Antisense to the A1 receptor suppressed A1 receptor immunoreactivity but did not show any neurot

217 esults suggest that CHU rats have functional A(1) receptors in heart and vasculature, but the release

218 vasodilatation and bradycardia by acting on A(1) receptors in normal (N) rats.

219 bilateral activation as well as blockade of A(1) receptors in the PF-LHA on sleep-wakefulness in fre

220 Conversely, over-expression of the cloned A1 receptor in CASMC increases adenosine- and CCPA-induc

221 nse oligonucleotides against the mRNA of the A1 receptor in the magnocellular cholinergic region of t

222 d we sought to explore the role of adenosine A1 receptors in a model of trigeminovascular nociceptive

223 on of emotional (fear) memories by acting on A1 receptors in brain regions underlying fear conditioni

224 in barrier, we examine the role of adenosine A1 receptors in mediating cortical blood flow and metabo

225 vitro studies supported roles for adenosine A1 receptors in promoting fatty acid synthesis and for A

226 he concentrations of adenosine and adenosine A1 receptors in specific regions of the brain.

227 ector to focally delete endogenous adenosine A1 receptors in the hippocampus.

228 evel but not of K(ATP) channels or adenosine A1 receptors in the preconditioning effects of CSD.

229 ence supporting the involvement of adenosine A1 receptors in the regulation of the response of the ci

230 HVR), and investigated the role of adenosine A1 receptors in these SF effects in conscious adult male

231 ur hypothesis that adenosine, acting via the A1 receptor, in the basal forebrain is a key component i

232 This effect requires functional adenosine A1 receptors, in line with the observation that ATP is r

233 role of adenosine--acting through adenosine A(1) receptors--in renal autoregulation has been clarifi

234 ibition of adenylyl cyclase with GABA(B) and A(1) receptors, indicating that these receptors are loca

235 onists and completely abolished by adenosine A(1) receptor inhibition.

236 .5 mM), but was not affected by an adenosine A1 receptor inhibitor, 8-cyclopentyl-1,3-dipropylxanthin

237 one of the sites where adenosine, acting via A(1) receptors, inhibits PF-LHA neurons to promote sleep

238 receptors and to decrease metabolic rate via A1 receptors inside the blood brain barrier.

239 While activation of inhibitory adenosine A(1) receptors is beneficial in epilepsy, chronic pain a

240 me in the mammalian fetus that the adenosine A1 receptor is an important mediator of brain metabolic

241 oxygen consumption, suggesting the adenosine A1 receptor is involved in lowering metabolic rate durin

242 hypothesized that adenosine, acting via the A1 receptor, is a key factor in the homeostatic control

243 protection of PostC was absent in adenosine A(1) receptor knockout mice (34.9+/-2.7%) or bradykinin

244 The bone mineral density (BMD) in adenosine A(1) receptor-knockout (A(1)R-knockout) mice was analyze

245 3-kinase/AKT pathways primarily through the A1 receptor, leading to CASMC mitogenesis.

246 ccompanies sleep deprivation, acting via the A1 receptor, led to activation of the transcription fact

247 have shown that the activation of adenosine A(1) receptors lower intraocular pressure primarily by i

248 These results suggest that the adenosine A(1) receptor may be a useful target in treating disease

249 recent evidence suggests that adenosine via A(1) receptors may act on PF-LHA neurons to promote slee

250 that heterologous attenuation of GABA(B) and A(1) receptor-mediated inhibition of adenylyl cyclase wa

251 ne, as measured indirectly as a reduction in A(1) receptor-mediated inhibition of glutamate excitator

252 el role for the PP2A holoenzyme in adenosine A(1) receptor-mediated regulation of NHE1 activity in AR

253 se results are considered in relation to the A(1)-receptor-mediated muscle dilatation evoked by syste

254 er, the cell-signaling mechanisms underlying A1 receptor-mediated CASMC proliferation in response to

255 ing extracellular adenosine, a loss of tonic A1 receptor-mediated inhibition.

256 n of a two-pore domain potassium channel and A1 receptor-mediated opening of a G-protein-coupled inwa

257 n increased both adenosine concentration and A1 receptor-mediated synaptic inhibition.

258 Adenosine A1 receptors modulate baseline synaptic transmission in

259 e A1 receptor, this AAV-Cre markedly reduced A1 receptor mRNA and focally abolished the postsynaptic

260 s directly reduces tremor, whereas adenosine A1 receptor-null mice show involuntary movements and sei

261 the sign of Sema6D and signals Nr-CAM/Plexin-A1 receptors on RGCs to implement the contralateral RGC

262 es adipogenesis through peripheral adenosine A(1) receptor (pADORA(1)) signaling; however, it remains

263 tor was cloned and expressed in COS-1 cells, A1 receptor pharmacology is confirmed.

264 endogenous adenosine acting at the neuronal A1 receptor plays a major role in the depression of syna

265 ow that blocking the activation of adenosine A1 receptors prevents the long-term depression (LTD) evo

266 s study revealed a 3-fold RA-to-LA adenosine A1 receptor protein expression gradient in the human hea

267 Adenosine A1 receptor protein expression was significantly upregul

268 fect, but those for adrenergic and adenosine A1 receptors reduced firing.

269 that tonically released adenosine acting on A1 receptors reduces HR in 1CH rats and stimulates endot

270 Upon solubilization, the retinal adenosine A1 receptor retained binding characteristics similar to

271 e, because of its ability to block adenosine A1 receptors, shares neurochemical properties with other

272 dnSNARE mice) or pharmacological blockade of A1 receptor signaling using an adenosine A1 receptor (A1

273 P and OT release also appeared to be via the A(1) receptor, since it was reversed by CPT.

274 These actions were mimicked by the A(1) receptor-specific agonist, N(6)-cyclopentyl-adenosi

275 herefore conclude that adenosine, acting via A(1) receptors, specifically blocks the terminal N-type

276 Adenosine A(1) receptor stimulation inhibits this response through

277 ates neuroprotection by activating adenosine A(1) receptor subtype (A(1)AR) linked to suppression of

278 The selectivity level over the adenosine A1 receptor subtype for some of the more active analogue

279 aptic mechanisms involving the activation of A1 receptors suppress tremor activity and limit stimulat

280 Antisense to the A1 receptor suppressed A1 receptor immunoreactivity but

281 ated by a pathway initiated at the adenosine A1 receptor that transduced signals through a Ca2+-activ

282 e results in elevated cell surface levels of A1 receptors, these cells will be more susceptible to ex

283 king the major coding exon for the adenosine A1 receptor, this AAV-Cre markedly reduced A1 receptor m

284 temic hypoxia, adenosine acts on endothelial A(1) receptors to increase PG synthesis, thereby generat

285 ting that adenosine signals strongly via the A1 receptor to these mitogenic signaling pathways.

286 ously released adenosine acts on endothelial A1 receptors to evoke dilatation in a NO-dependent fashi

287 mediated by adenosine acting at endothelial A1 receptors to stimulate synthesis and release of NO, w

288 ent, we could detect little or no inhibitory A(1) receptor tone in basal conditions and during trains

289 In chronic HF, adenosine A1 receptor upregulation in SAN pacemaker and atrial car

290 However, G protein activation by GABA(B) or A(1) receptors was unaffected.

291 When a cDNA encoding the porcine A1 receptor was cloned and expressed in COS-1 cells, A1

292 oval was required to prevent ouabain-SD when A(1) receptors were blocked.

293 In addition, we found that adenosine A1 receptors were required for astrocyte calcium activat

294 As an example we show that the adenosine A1 receptor, when placed under the influence of the mous

295 glion cells is produced by the activation of A(1) receptors, which initiates a signaling cascade that

296 Immature and mature synapses expressed A1 receptors with no observable difference in functional

297 potentiate agonist [(3)H]CCPA binding to the A1 receptor, with 4e as the best compound of the series.

298 esults provide novel evidence that adenosine A(1) receptors within the prefrontal cortex comprise par

299 This A1-receptor-Y(288)A was retained in the ER of stably tra

300 mbination and enhanced surface expression of A1-receptor-Y(288)A within 1 hour.